Failed German price negotiations likely to lead to heavy pan-EU discounts
This article was originally published in Scrip
Executive Summary
Companies that fail to thrash out a price with German health insurers following early benefit assessments are likely to end up with prices based on a basket of 80% of Euro countries. Such a move would mean lower prices as even troubled countries like Greece could have an impact on German prices, warns the BPI industry organisation, which represents small to medium sized companies.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.